REVIEW PAPER
Diagnostic value of selected markers and apoptotic pathways for pancreatic cancer
Submission date: 2016-09-09
Final revision date: 2016-09-16
Acceptance date: 2016-09-26
Publication date: 2017-01-24
Cent Eur J Immunol 2016;41(4):392-403
KEYWORDS
ABSTRACT
Pancreatic cancer occupies the fourth place as a cause of death from cancer, and the mortality rate is similar to the number of newly detected cases. Due to the late diagnosis, only 5-6% of patients with pancreatic cancer survive for five years. Given that early diagnosis is critical for improving patients’ survival rates, there is an urgent need for the discovery and validation of new biomarkers with sufficient sensitivity and specificity to help diagnose pancreatic cancer early. Detection of serum tumor markers (CA19-9, CEA, CA125 and CA242) is conducive to the early diagnosis of pancreatic cancer. The combination of miR-16, miR-196a and CA19-9 plasma level was more effective, especially in early tumor screening. Furthermore, recent studies reported that mainly miR-21, miR-155 and miR-196 were dysregulated in IPMN (intraductal papillary mucinous neoplasms) and PanIN (pancreatic intraepithelial neoplasia) lesions, suggesting their usefulness as early biomarkers of these diseases. The reduced rate of apoptosis plays a crucial role in carcinogenesis, and it is one of the most important characteristics acquired by pancreatic cancer cells, which protects them from attack by the immune system and reduces the effectiveness of pharmacological treatment. This review summarizes the data concerning the clinical utility of selected biomarkers in pancreatic cancer patients. The review mainly focuses on the genetic aspects of signaling pathway disorders associated with apoptosis in the pathogenesis and diagnosis of pancreatic cancer.
REFERENCES (149)
1.
Jemal A, Siegiel R, Xu J, Ward E (2010): Cancer Statistica 2010. CA Cancer J Clin 60: 277-300.
2.
Bosetti C, Bertuccio P, Negri E, et al. (2012): Pancreatic cancer: overview of descriptive epidemiology. Mol Carcinog 51: 3-13.
3.
Bosetti C, Bertuccio P, Malvezzi M, et al. (2013): Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980. Ann Oncol 24: 2657-2671.
4.
Conroy T, Desseigne F, Ychou M, et al. (2011): The Groupe Tumeurs Digestives of Unicancer and the PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825.
5.
Klapman J, Malafa MP (2008): Early detection of pancreatic cancer: why, who, and how to screen. Cancer Control 15: 280-287.
6.
Lowenfels AB, Maisonneuve P, Cavallini G, et al. (1993): Pancreatitis and the risk of pancreatic cancer. N Engl J Med 328: 1433-1437.
7.
McKay CJ, Glen P, McMillan DC (2008): Chronic inflammation and pancreatic cancer. Best Pract Res Clin Gastroenterol 22: 65-73.
8.
Raimondi S, Lowenfels AB, Morselli-Labate AM, et al. (2010): Pancreatic cancer in chronic pancreatitis; etiology, incidence, and early detection. Best Pract Res Clin Gastroenterol 24: 349-358.
9.
Lowenfels AB, Maisonneuve P, DiMagno EP, et al. (1997): Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 89: 442-446.
10.
Klein AP (2012): Genetic susceptibility to pancreatic cancer. Mol Carcinog 51: 14-24.
11.
Raimondi S, Maisonneuve P, Lowenfels AB (2009): Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 6: 699-708.
12.
Hassan MM, Bondy ML, Wolff RA, et al. (2007): Risk factors for pancreatic cancer: case control study. Am J Gastroenterol 102: 2696-2707.
13.
Lynch SM, Vrieling A, Lubin JH, et al. (2009): Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Am J Epidemiol 170: 403-413.
14.
Chari ST, Leibson CL, Rabe KG, et al. (2005): Probability of pancreatic cancer following diabetes: A population-based study. Gastroenterology 129: 504-511.
15.
Pannala R, Basu A, Petersen GM, Chari ST (2009): New-onset Diabetes: A Potential Clue to the Early Diagnosis of Pancreatic Cancer. Lancet Oncol 10: 88-95.
16.
Ben Q, Xu M, Ning X, et al. (2011): Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer 47: 1928-1937.
17.
Magruder JT, Elahi D, Andersen DK (2011): Diabetes and pancreatic cancer:chicken or egg? Pancreas 40: 339-351.
18.
Pezzilli R, Pagano N (2013): Is diabetes mellitus a risk factor for pancreatic cancer? World J Gastroenterol 19: 4861-4866.
19.
Klein AP, Brune KA, Petersen GM (2004): Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64: 2634-2638.
20.
Korsse SE, Harinck F, van Lier MG, et al. (2013): Pancreatic cancer risk in Peutz-Jeghers syndrome patients: a large cohort study and implications for surveillance. J Med Genet 50: 59-64.
21.
Kastrinos F, Mukherjee B, Tayob N, et al. (2009): Risk of Pancreatic Cancer in Families With Lynch Syndrome. JAMA 302: 1790-1795.
22.
Weiss F (2014): Pancreatic cancer risk in hereditary pancreatitis. Front Physiol 5: 1-5.
23.
van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, et al. (2005): Netherlands Collaborative Group on Hereditary Breast Cancer (HEBON) Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 42: 711-719.
24.
Thompson D, Easton DF (2002): Breast Cancer Linkage Consortium. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94: 1358-1365.
25.
Yachida S, Iacobuzio-Donahue CA (2013): Evolution and dynamics of pancreatic cancer progression. Oncogene 32: 5253-5260.
26.
Shin SH, Kim SC, Hong SM, et al. (2013): Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival. Pancreas 42: 216-222.
27.
Huggett MT, Pereira SP (2011): Diagnosing and managing pancreatic cancer. Practitioner 255: 21-33.
28.
Al-Sukhni W, Borgida A, Rothenmund H, et al. (2012): Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. J Gastrointest Surg 16: 771-783.
29.
Kent OA, Mullendore M, Wentzel EA, et al. (2009): A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther 8: 2013-2024.
30.
Yonezawa S, Higashi M, Yamada N, Goto M (2008): Precursor lesions of pancreatic cancer. Gut Liver 2: 137-154.
31.
Schneider G, Schmid RM (2003): Genetic alterations in pancreatic carcinoma. Molecular Cancer 2: 1-7.
32.
Jones S, Zhang X, Parsons DW, et al. (2008): Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-6.
33.
Oshima M, Okano K, Muraki S, et al. (2013): Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Ann Surg 258: 336-346.
34.
Jiang H, He C, Geng S, et al. (2012): RhoT1 and Smad4 are correlated with lymph node metastasis and overall survival in pancreatic cancer. PLoS One 7: e42234.
35.
Zhang L, Farrell JJ, Zhou H, et al. (2010): Salivary Transcriptomic Biomarkers for Detection of Resectable Pancreatic Cancer Gastroenterology 138: 949-957.
36.
Biankin AV, Waddell N, Kassahn KS, et al. (2012): Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491: 399-405.
37.
Waddell N, Pajic M, Patch AM, et al. (2015): Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518: 495-501.
38.
Campbell PJ, Yachida S, Mudie LJ, et al. (2010): The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467: 1109-1113.
39.
Yachida S, Jones S, Bozic I, et al. (2010): Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114-1117.
40.
Ballehaninna UK, Chamberlain RS (2012): The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol 3: 105-119.
41.
Goonetilleke KS, Siriwardena AK (2007): Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33: 266-270.
42.
Maithel SK, Maloney S, Winston C, et al. (2008): Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol 15: 3512-3520.
43.
Kim YC, Kim HJ, Park JH, et al. (2009): Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma? J Gastroenterol Hepatol 24: 1869-1875.
44.
Zhang Y, Yang J, Li H, et al. (2015): Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis. Int J Clin Exp Med 8: 11683-11691.
45.
Gu YL, Lan Ch, Pei H, et al. (2015): Applicative value of serum CA19-9, CEA, CA125 and CA242 in diagnosis and prognosis for patients with pancreatic cancer treated by concurrent chemoradiotherapy. Asian Pac J Cancer Prev 16: 6569-6573.
46.
Parikh DA, Durbin-Johnson B, Urayama S (2014): Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population. J Gastrointest Cancer 45: 74-79.
47.
O’Brien DP, Sandanayake NS, Jenkinson C, et al. (2015): Serum CA19-9 is significantly up-regulated up to 2 years prior to diagnosis with pancreatic cancer: implications for early disease detection. Clin Cancer Res 21: 622-631.
48.
Liu J, Gao J, Du Y, et al. (2012): Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer 131: 683-691.
49.
Schultz NA, Dehlendorff C, Jensen BV, et al. (2014): MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA 311: 392-404.
50.
Buchsbaum DJ, Croce CM (2014): Will detection of MicroRNA biomarkers in blood improve the diagnosis and survival of patients with pancreatic cancer? JAMA 311: 363-365.
51.
Yu J, Li A, Hong SM, et al. (2012): MicroRNA Alterations of Pancreatic Intraepithelial Neoplasms (PanINs) Clin Cancer Res 18: 981-992.
52.
Hernandez YG, Lucas AL (2016): MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions. World J Gastrointest Oncol 8: 18-29.
53.
Simeone DM, Ji B, Banerjee M, Arumugam T, et al. (2007): CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas 34: 436-443.
54.
Ingvarsson J, Wingren C, Carlsson A, et al. (2008): Detection of pancreatic cancer using antibody microarray-based serum protein profiling. Proteomics 8: 2211-2219.
55.
Winter M, Ting AH, Vilardell F, et al. (2008): Absence of E-Cadherin Expression Distinguishes Noncohesive from Cohesive Pancreatic Cancer. Clin Cancer Res 14: 412-418.
56.
Joergensen MT, Brünner N, De Muckadell OB (2010): Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer. Anticancer Research 30: 587-592.
57.
Honda K, Kobayashi M, Okusaka T, et al. (2015): Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms. Sci Rep 5: 15921(1-15).
58.
Felix K, Gaida MM (2016): Neutrophil-derived proteases in the microenvironment of pancreatic cancer –active players in tumor progression. Int J Biol Sci 12: 302-313.
59.
Tian M, Cui YZ, Song GH, et al. (2008): Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 8: 241-252.
60.
Gregory AD, Houghton AM (2011): Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 71: 2411-2416.
61.
Yang JJ, Hu ZG, Shi WX, et al. (2015): Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: A meta-analysis. World J Gastroenterol 21: 2807-2815.
62.
Reid MD, Basturk O, Thirabanjasak D, et al. (2011): Tumor-infiltrating neutrophils in pancreatic neoplasia. Mod Pathol 24: 1612-1619.
63.
Chen KT, Kim PD, Jones KA, et al. (2014): Potential prognostic biomarkers of pancreatic cancer. Pancreas 43: 22-27.
64.
Xu C, Wallace MB, Yang J, et al. (2014): ZIP4 is a novel diagnostic and prognostic marker in human pancreatic cancer: a systemic comparison between EUS-FNA and surgical specimens. Curr Mol Med 14: 309-315.
65.
Kaur S, Chakraborty S, Baine MJ, et al. (2013): Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer. PLoS One 8: e55171.
66.
Koopmann J, Buckhaults P, Brown DA, et al. (2004): Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clinical Cancer Research 10: 2386-2392.
67.
El-Mesallamy HO, Hamdy NM, Zaghloul AS, Sallam AM (2013): Clinical value of circulating lipocalins and insulin-like growth factor axis in pancreatic cancer diagnosis. Pancreas 42: 149-154.
68.
Lopez T, Hanahan D (2002): Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 1: 339-353.
69.
Dutta SK, Girotra M, Singla M, et al. (2012): Serum HSP70: a novel biomarker for early detection of pancreatic cancer. Pancreas 41: 530-534.
70.
Melo SA, Luecke LB, Kahlert C, et al. (2015): Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523: 177-182.
71.
Gerdtsson AS, Malats N, Säll A, et al. (2015): A Multicenter Trial Defining a Serum Protein Signature Associated with Pancreatic Ductal Adenocarcinoma. Int J Proteomics 2015: 587250.
72.
Shaw VE, Lane B, Jenkinson C, et al. (2014): Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease. Mol Cancer 13: 114.
73.
Wingren C, Sandström A, Segersvärd R, et al. (2012): Identification of serum biomarker signatures associated with pancreatic cancer. Cancer Res 72: 2481-2490.
74.
Grote VA, Kaaks R, Nieters A, et al. (2012): Inflammation marker and risk of pancreatic cancer: a nested case-control study within the EPIC cohort. Br J Cancer 106: 1866-1874.
75.
Bao Y, Giovannucci EL, Kraft P, et al. (2013): Inflammatory Plasma Markers and Pancreatic Cancer Risk: a Prospective Study of 5 U.S. Cohorts. Cancer Epidemiol Biomarkers Prev 22: 855-861.
77.
Hanahan D, Weinberg RA (2011): Hallmarks of Cancer: The Next Generation. Cell 144: 646-674.
78.
Wong HH, Lemoine NR (2009): Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol 6: 412-422.
79.
Fulda S, Galluzzi L, Kroemer G (2010): Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 9: 447-464.
80.
Wang RA, Li ZS, Yan QG, et al. (2014): Resistance to apoptosis should not be taken as a hallmark of cancer. Chin.
82.
Wong RSY (2011): Apoptosis in cancer: from pathogenesis to treatment. Journal of Experimental and Clinical Cancer Research 30: 87.
83.
Trauzold A, Wermann H, Arlt A, et al. (2001): CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-B contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene 20: 4258-4269.
84.
Hinz S, Trauzold A, Boenicke L, et al. (2000): Bcl-XL protects pancreatic adenocarcinoma cells against CD95– and TRAIL-receptor-mediated apoptosis. Oncogene 19: 5477-5486.
85.
Lüttges J, Neumann S, Jesenofsky R, et al. (2003): Lack of apoptosis in PanIN-1 and PanIN-2 lesions associated with pancreatic ductal adenocarcinoma is not dependent on K-ras status. Pancreas 27: e57-62.
86.
Fulda S (2007): Inhibitor of apoptosis proteins as targets for anticancer therapy. Expert Rev Anticancer Ther 7: 1255-1264.
87.
Bhanot U, Heydrich R, Moller P, Hasel C (2006): Survivin expression in pancreatic intraepithelial neoplasia (PanIN): steady increase along the developmental stages of pancreatic ductal adenocarcinoma. Am J Surg Pathol 30: 754-759.
88.
Lopes RB, Gangeswaran R, McNeish IA, et al. (2007): Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy. Int J Cancer 120: 2344-2352.
89.
Esposito I, Kleeff J, Abiatari I, et al. (2007): Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer. J Clin Pathol 60: 885-895.
90.
Trauzold A, Schmiedel S, Roder C, et al. (2003): Multiple and synergistic deregulations of apoptosis-controlling genes in pancreatic carcinoma cells. Br J Cancer 89: 1714-1721.
91.
Ungefroren H, Voss M, Jansen M, et al. (1998): Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res 58: 1741-1749.
92.
Ungefroren H, Kruse ML, Trauzold A, et al. (2001): FAP-1 in pancreatic cancer cells: functional and mechanistic studies on its inhibitory role in CD95-mediated apoptosis. J Cell Sci 114: 2735-2746.
93.
Elnemr A, Ohta T, Yachie A, et al. (2001): Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway. Int J Oncol 18: 311-316.
94.
Trauzold A, Roder C, Sipos B, et al. (2005): CD95 and TRAF2 promote invasiveness of pancreatic cancer cells. Faseb J 19: 620-622.
95.
Greten FR, Weber CK, Greten TF, et al. (2002): Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology 123: 2052-2063.
96.
Evans JD, Cornford PA, Dodson A, et al. (2001): Detailed tissue expression of bcl-2, bax, bak and bcl-x in the normal human pancreas and in chronic pancreatitis, ampullary and pancreatic ductal adenocarcinomas. Pancreatology 1: 254-262.
97.
Magistrelli P, Coppola R, Tonini G, et al. (2006): Apoptotic index or a combination of Bax/Bcl-2 expression correlate with survival after resection of pancreatic adenocarcinoma. J Cell Biochem 97: 98-108.
98.
Cowley MJ, Chang DK, Pajic M, et al. (2013): Understanding pancreatic cancer genomes. J Hepatobiliary Pancreat Sci 20: 549-556.
99.
Collisson EA, Sadanandam A, Olson P, et al. (2011): Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 17: 500-503.
100.
Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D (2011): RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 11: 761-774.
101.
Steele CW, Jamieson NB, Evans TR, et al. (2013): Exploiting inflammation for therapeutic gain in pancreatic cancer. Br J Cancer 108: 997-1003.
102.
Kurahara H, Shinchi H, Mataki Y, et al. (2011): Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res 167: e211-e219.
103.
Baran B, Bechyne I, Siedlar M, et al. (2009): Blood monocytes stimulate migration of human pancreatic carcinoma cells in vitro: the role of tumour necrosis factor-alpha. Eur J Cell Biol 88: 743-752.
104.
Collins MA, Bednar F, Zhang Y, et al. (2012): Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest 122: 639-653.
105.
Guerra C, Schuhmacher AJ, Cańamero M, et al. (2007): Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11: 291-302.
106.
Reichert M, Rustgi AK (2011): Pancreatic ductal cells in development, regeneration, and neoplasia. J Clin Invest 121: 4572-4578.
107.
Kopp JL, von Figura G, Mayes E, et al. (2012): Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer Cell 22: 737-750.
108.
Chen NM, Singh G, Koenig A, et al. (2015): NFATc1 Links EGFR Signaling to Induction of Sox9 Transcription and Acinar–Ductal Transdifferentiation in the Pancreas. Gastroenterology 148: 1024-1034.
109.
Baumgart S, Chen NM, Siveke JT, et al. (2014): Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D. Cancer Discov 4: 688-701.
110.
di Magliano MP, Logsdon CD (2013): Roles for KRAS in pancreatic tumor development and progression. Gastroenterology 144: 1220-1229.
111.
Rachagani S, Senapati S, Chakraborty S, et al. (2011): Activated KrasG12D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. Br J Cancer 104: 1038-1048.
112.
Falasca M, Selvaggi F, Buus R, et al. (2011): Targeting phosphoinositide 3-kinase pathways in pancreatic cancer – from molecular signalling to clinical trials. Anticancer Agents Med Chem 11: 455-463.
113.
Edling CE, Selvaggi F, Buus R, et al. (2010): Key role of phosphoinositide 3-kinase class IB in pancreatic cancer. Clin Cancer Res 16: 4928-4937.
114.
Schmid MC, Avraamides CJ, Dippold HC, et al. (2011): Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3k, a single convergent point promoting tumor inflammation and progression. Cancer Cell 19: 715-727.
115.
Asano T, Yao Y, Zhu J, et al. (2004): The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 23: 8571-8580.
116.
Yamada KM, Araki M (2001): Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci 114: 2375-2382.
117.
Weng LP, Gimm O, Kum JB, et al. (2001): Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death. Human Molecular Genetics 10: 251-258.
118.
Foo WCh, Rashid A, Wang H, et al. (2013): Loss of PTEN Expression Is Associated with Recurrence and Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma. Hum Pathol 44: 1024-1030.
120.
Bleeker FE, Felicioni L, Buttitta F, et al. (2008): AKT1(E17K) in human solid tumours. Oncogene 27: 5648-5650.
121.
Vousden KH. Prives C (2009): Blinded by the Light: The Growing Complexity of p53. Cell 137: 413-431.
122.
Li D, Xie K, Wolff R, Abbruzzese JL (2004): Pancreatic cancer. Lancet 363: 1049-1057.
123.
Rozenblum E, Schutte M, Goggins M, et al. (1997): Tumor-suppressive Pathways in Pancreatic Carcinoma. Cancer Res 57: 1731-1734.
124.
Weissmueller S, Manchado E, Saborowski M, et al. (2014): Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor signaling. Cell 157: 382-394.
125.
Xiang J-F, Wang WQ, Liu L, et al. (2016): Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9 ≥ 1,000 U/mL. Sci Rep 6: 19222.
126.
Karin M (2006): Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436.
127.
Levine AJ, Oren M (2009): The first 30 years of p53: growing ever more complex. Nat Rev Cancer 9: 749-758.
128.
Lu T, Burdelya LG, Swiatkowski SM, et al. (2004): Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells. Proc Natl Acad Sci U S A 101: 7112-7117.
129.
Wang W, Abbruzzese JL, Evans DB, et al. (1999): The nuclear factor-nB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 5: 119-127.
130.
Fujioka S, Sclabas GM, Schmidt C, et al. (2003): Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis. Oncogene 22: 1365-1370.
131.
Ling J, Kang Y, Zhao R, et al. (2012): KrasG12D-induced IKK2//NF-B activation by IL-1 and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 21: 105-120.
132.
Fan X, Zhang X, Shen J, et al. (2016): Decreased TUSC3 Promotes Pancreatic Cancer Proliferation, Invasion and Metastasis. PLoS One 11: e0149028.
133.
Ye HL, Li DD, Lin Q, et al. (2015): Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival. World J Gastroenterol 21: 6621-6630.
134.
Iwasa H, Jiang X, Hata Y (2015): RASSF6; the Putative Tumor Suppressor of the RASSF Family. Cancers 7: 2415-2426.
135.
Volodko N, Gordon M, Salla M, et al. (2014): RASSF tumor suppressor gene family: biological functions and regulation. FEBS Lett 588: 2671-2684.
136.
van der Weyden L, Adams DJ (2007): The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta 1776: 58-85.
137.
Allen NP, Donninger H, Vos MD, et al. (2007): RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene 26: 6203-6211.
138.
Ikeda M, Hirabayashi S, Fujiwara N, et al. (2007): Ras-association domain family protein 6 induces apoptosis via both caspase-dependent and caspase-independent pathways. Exp Cell Res 313: 1484-1495.
139.
Tahira AC, Kubrusly MS, Faria MF, et al. (2011): Long noncoding intronic RNAs are differentially expressed in primary and metastatic pancreatic cancer. Mol Cancer 10: 141.
140.
Ting DT, Lipson D, Paul S, et al. (2011): Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers. Science 331: 593-596.
141.
Kim K, Jutooru I, Chadalapaka G, et al. (2013): HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene 32: 1616-1625.
142.
Zhou M, Ye Z, Gu Y, et al. (2015): Genomic analysis of drug resistant pancreatic cancer cell line by combining long non-coding RNA and mRNA expression profling. Int J Clin Exp Pathol 8: 38-52.
143.
Li DD, Fu ZQ, Lin Q, et al. (2015): Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma. World J Gastroenterol 21: 9348-9357.
144.
Li Z, Zhao X, Zhou Y, et al. (2015): The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer. J Transl Med 13: 84.
145.
Cheng Y, Jutooru I, Chadalapaka G, et al. (2015): The long non-coding RNA HOTTIP enhances pancreatic cancer cell proliferation, survival and migration. Oncotarget 6: 10840-10852.
146.
Gutschner T, Diederichs S (2012): The hallmarks of cancer: a long noncoding RNA point of view. RNA Biol 9: 703-719.
147.
Gupta RA, Shah N, Wang KC, et al. (2010): Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464: 1071-1076.
148.
Słotwiński R, Olszewski WL, Słodkowski M, et al. (2011): Apoptosis in lymphocytes of pancreatic cancer patients: influence of preoperative enteral immunonutrition and extensive surgery. Arch Immunol Ther Exp 59: 385-397.
149.
Morris JP, Wang SC, Hebrok M (2010): KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 10: 683-695.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
